Healthcare Value Capital’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Healthcare Value Capital’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-18,750	Closed	-$3.45M	–	11
2018 Q4	$3.45M	Hold	18,750	–	–	13.41%	4
2018 Q3	$2.35M	Hold	18,750	–	–	5.67%	9
2018 Q2	$2.92M	Buy	18,750 +9,375	+100%	+$1.56M	8.28%	6
2018 Q1	$1.59M	Buy	9,375 +6,250	+200%	+$1M	6.61%	6
2017 Q4	$551K	Hold	3,125	–	–	1.68%	8
2017 Q3	$514K	Hold	3,125	–	–	1.03%	11
2017 Q2	$606K	Buy	+3,125	New	+$681K	1.09%	15
2015 Q3	–	Sell	-12,500	Closed	-$2.87M	–	30
2015 Q2	$2.87M	Hold	12,500	–	–	3.02%	13
2015 Q1	$3.45M	Buy	+12,500	New	+$3.83M	3.76%	10
2014 Q4	–	Sell	-5,000	Closed	-$2.41M	–	29
2014 Q3	$2.41M	Hold	5,000	–	–	2.32%	16
2014 Q2	$2.85M	Buy	5,000 +1,875	+60%	+$1.29M	2.39%	14
2014 Q1	$2.23M	Buy	+3,125	New	+$2.09M	1.46%	21

Other funds holding BIS

WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare Value Capital's BIS Position: Q1 2019 in Review

Healthcare Value Capital sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2019, closing a stake of 18,750 shares — an estimated $3.45M sold.

Healthcare Value Capital first reported a position in BIS in Q1 2014 and held it in 12 quarters. The position peaked at $3.45M in Q1 2015. 8 funds tracked by Wall St. Rank hold BIS as of Q1 2019.

Healthcare Value Capital reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2019 after selling out during the quarter.
Healthcare Value Capital sold 18,750 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2019, an estimated $3.45M.
Healthcare Value Capital first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q1 2014 and held it in 12 quarters.
Healthcare Value Capital's ProShares UltraShort NASDAQ Biotechnology position peaked at $3.45M in Q1 2015.
8 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2019.

Based on Healthcare Value Capital's 13F filing for Q1 2019, filed 14 May 2019.